Thursday, February 5, 2009

IMPAX Receives Final FDA Approval for Generic Minocycline hydrochloride Extended-Release Tablets, 45mg, 90mg and 135mg

Feb 5, 2009 - IMPAX Laboratories, Inc. today confirmed that the U.S. FDA has granted final approval of the Company's Abbreviated New Drug Application for generic versions of SOLODYN (minocycline HCI) 45mg, 90mg and 135mg Extended-release Tablets. Medicis markets SOLODYN for the treatment of moderate-to-severe acne.

The details can be read here.

No comments: